Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Drops By 15.0%

KALA BIO, Inc. (NASDAQ:KALA) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 5,100 shares, a drop of 15.0% from the March 31st total of 6,000 shares. Based on an average daily volume of 20,500 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are short sold.

KALA BIO Trading Up 1.9 %

NASDAQ KALA opened at $6.30 on Monday. The company has a market cap of $17.77 million, a PE ratio of -0.35 and a beta of -1.85. KALA BIO has a 12 month low of $5.10 and a 12 month high of $19.35. The stock has a 50 day moving average of $7.37 and a 200-day moving average of $7.14. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 5.10.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Friday, March 29th. The company reported ($3.18) earnings per share for the quarter. On average, equities research analysts anticipate that KALA BIO will post -11.28 EPS for the current fiscal year.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research report on Monday, April 1st. HC Wainwright dropped their target price on KALA BIO from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.